Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Lenalidomide maintenance for transplant eligible and transplant ineligible...

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Dasatinib vs imatinib in the treatment of paediatric ALL

Dr Shuhong Shen - National Children's Medical Center, Shanghai, China

Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells...

Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern...

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )

Prognostic impact of chromosomal abnormalities and copy number alterations in B...

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14 ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )

Long-term outcomes of subjects with EBV driven PTLD following solid organ or...

Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel ( Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA )

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT...

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )

Outcomes in patients with therapy-Related AML who achieved remission with CPX...

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa...

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

LYRA: Maintenance therapy with daratumumab improves depth of response and...

Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA

LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )

KRd consolidation in MM patients with a positive PET-CT after standard first...

Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway

KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )

More from ecancer